2023
DOI: 10.1002/adma.202307263
|View full text |Cite
|
Sign up to set email alerts
|

Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo‐Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment

Yunkun Li,
Yahui Wu,
Zaixiang Fang
et al.

Abstract: Unsatisfied tumor accumulation of chemotherapeutic drugs and a complicated immunosuppressive microenvironment diminish the immune response rate and the therapeutic effect. Surface modification of these drugs with target ligands can promote their cellular internalization, but the modified drugs may be subjected to unexpected immune recognition and clearance. Herein, a phenylboronic acid (PBA) group‐shieldable dendritic nanomedicine that integrates an immunogenic cell death (ICD)‐inducing agent (epirubicin, Epi)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 58 publications
0
4
0
Order By: Relevance
“…A significantly reduced percentage of MDSCs (Gr-1 + CD11b + ) and Tregs (CD3 + CD4 + Foxp3 + ) was observed in the mHM@HMME+US group (Figure I–L), revealing that the treatment with mHM@HMME+US can alleviate the immunosuppressive tumor microenvironment. Furthermore, pro-inflammatory cytokines (including the TNF-α, IFN-γ, IL-6, and IL-1β) were analyzed by the ELISA assay. , As shown in Figure M–P, the secretion of TNF-α, IFN-γ, IL-6, and IL-1β is highest in the mHM@HMME+US group, demonstrating the effect of mHM@HMME+US in the enhanced activation of antitumor immune responses.…”
Section: Resultsmentioning
confidence: 94%
See 1 more Smart Citation
“…A significantly reduced percentage of MDSCs (Gr-1 + CD11b + ) and Tregs (CD3 + CD4 + Foxp3 + ) was observed in the mHM@HMME+US group (Figure I–L), revealing that the treatment with mHM@HMME+US can alleviate the immunosuppressive tumor microenvironment. Furthermore, pro-inflammatory cytokines (including the TNF-α, IFN-γ, IL-6, and IL-1β) were analyzed by the ELISA assay. , As shown in Figure M–P, the secretion of TNF-α, IFN-γ, IL-6, and IL-1β is highest in the mHM@HMME+US group, demonstrating the effect of mHM@HMME+US in the enhanced activation of antitumor immune responses.…”
Section: Resultsmentioning
confidence: 94%
“…Furthermore, pro-inflammatory cytokines (including the TNFα, IFN-γ, IL-6, and IL-1β) were analyzed by the ELISA assay. 53,54 As shown in Figure 7M−P, the secretion of TNF-α, IFN-γ, IL-6, and IL-1β is highest in the mHM@HMME+US group, demonstrating the effect of mHM@HMME+US in the enhanced activation of antitumor immune responses.…”
Section: In Vivo Antitumor Efficiency and Biosafetymentioning
confidence: 88%
“…Various nanoparticles (NPs), including liposomes, inorganic NPs, and polymer NPs, have been investigated to enhance the bioavailability and therapeutic efficacy of cargoes, highlighting the potential of NP-based delivery systems for IDO1 inhibitors [ 18 20 ]. However, tumor immunotherapy based solely on IDO1 inhibition may produce limited therapeutic effects in practice due to the scarce infiltration of CD8 + T cells in tumors [ 21 ]. Therefore, combinatorial regimens employing IDO inhibitors and other therapeutic strategies that recruit more CD8 + T cells are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…NLG919 suppresses IDO signaling pathway by suppressing the enzymatic conversion of tryptophan (Trp) to kynurenine (Kyn) . More importantly, preclinical evidence reveals that the combination of NLG919 and chemotherapy dramatically amplifies therapeutic outcomes, combining the merits of both approaches. , Therefore, co-delivering NLG919 and AQ4N is imperative for improving the immunotherapy of HIFU surgery.…”
Section: Introductionmentioning
confidence: 99%